Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2

J Dtsch Dermatol Ges. 2022 Aug;20(8):1123-1124. doi: 10.1111/ddg.14784. Epub 2022 Jun 14.

Authors

Yuval Ramot¹, Krassimira Nanova², Sofia-Maria Faitatziadou¹, Dania Abu Assab¹, Yackov Berkun³, Abraham Zlotogorski¹

Affiliations

¹ Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
² Clalit Health Services, Jerusalem, Israel.
³ Department of Pediatrics, Hadassah Mount Scopus Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Pityriasis Rosea* / diagnosis
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines
BNT162 Vaccine